NPS Pharmaceuticals Inc. (NPSP) is in the Pharma Industry

• Sort by

• NPS Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator instructions And your first question comes from the line of May-Kin Ho from Goldman Sachs. Please proceed. Davis Bu – Goldman Sachs Hi, this is Davis Bu for May-Kin Ho. Unfortunately she had to step out. I have a couple of questions. First on...

  Earnings calls 2008-09-01

  Tags: NPS Pharmaceuticals Inc.

Additional Resources

• One Year of GATTEX™ Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome

  -- Results Presented at American College of Gastroenterology Annual Meeting Show Majority of Responders Continued to Benefit from GATTEX in Phase 3-Extension Study -- ORLANDO, Fla. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today presented positive one-year data from a Phase 3-extension study of GATTEX[TM] teduglutide, an investigational product...

  Articles 2008-10-08

• GATTEX™ Abstracts to be Presented at ACG Meeting; 52-Week Data from Phase 3 Clinical Trial Scheduled for Plenary Session

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported that three abstracts summarizing data from the company's Phase 3 studies of GATTEX[TM] teduglutide in patients with short bowel syndrome SBS were accepted for presentation at the American College of Gastroenterology ACG Annual Scientific Meeting and Postgraduate Course in Orlando,...

  Articles 2008-09-23

• NPS Pharmaceuticals to Report Second Quarter 2008 Financial Results

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its second quarter 2008 financial results on Thursday, August 7, 2008 post-market. The announcement will be followed by a conference call and webcast at 4:30 pm Eastern Time. To participate in the conference call,...

  Articles 2008-07-29

• NPS Pharmaceuticals to Present at Jefferies Healthcare Conference

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the Jefferies 2nd Annual Healthcare Conference in New York on Thursday, June 26, 2008 at 8:30 a.m. ET. The presentation will be available...

  Articles 2008-06-18

• NPS Pharmaceuticals Notified of ANDA Filings for Cinacalcet HCl

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the receipt of Paragraph IV Certification Notice Letters related to certain drug manufacturers' Abbreviated New Drug Applications ANDA submitted to the U.S. Food and Drug Administration FDA requesting approval to market and sell generic versions of Sensipar([R])...

  Articles 2008-06-16

• Now In Its Fourth Year, 'The CNS Market 2008 Report' Is an Expanded and Updated 400 Page Report of Brain and Nervous System Markets and Treatments

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/ab0827/the_cns_market_200) has announced the addition of the "The CNS Market 2008 Report" published by NeuroInsights to their offering. Drugs, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease...

  Articles 2008-06-12

• AGENCIES

  AbelsonTaylor promoted Ben Murphy and hired Sara Alien and Ryan Jones to boost its interactive division. Murphy has been promoted to senior interactive developer from interactive developer, and will be working on a product for the treatment of GERD. As interactive developer, Alien will be creating interactive sales aids,...

  Articles 2008-06-01

• Phase 3 GATTEX™ Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome

  Data Show GATTEX Reduces Parenteral Nutrition Requirements for SBS Patients SAN DIEGO -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the presentation of Phase 3 data at the annual Digestive Disease Week DDW Congress on GATTEX[TM] teduglutide, a novel investigational compound that may reduce dependence upon parenteral nutrition...

  Articles 2008-05-19

• NPS Appoints Dr. Bo Joelsson as Head of Clinical Research

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) announced today the appointment of Bo Joelsson, M.D., Ph.D., as head of clinical research reporting to Alan Harris, M.D., Ph.D., senior vice president R & D and chief medical officer of NPS. One of Dr. Joelsson's key responsibilities at NPS will be...

  Articles 2008-05-13

• GATTEX™ Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced that three abstracts related to the company's development program for GATTEX[TM] teduglutide for intestinal failure associated with short bowel syndrome SBS were accepted for presentation at the 2008 Digestive Disease Week DDW conference in San Diego May 17-22, 2008. The...

  Articles 2008-05-08

• NPS Pharmaceuticals Reports First Quarter 2008 Financial Results and Business Update

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported its financial results for the first quarter of 2008. Revenues increased to $25.2 million for the first quarter of 2008, as compared to $10.0 million for the first quarter of 2007. Operating expenses decreased to $20.1 million for the first...

  Articles 2008-05-07

• NPS Pharmaceuticals to Report First Quarter 2008 Financial Results

  BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its first quarter 2008 financial results on Wednesday, May 7, 2008 post-market. The announcement will be followed by a conference call and webcast at 5:00 pm Eastern Time. To participate in the conference call,...

  Articles 2008-04-29

• NPSP, NURO, PCYC, STEN, TONE, ATNO Have Also Been Removed From Naked Short List Today.

  M2 PRESSWIRE-31 March 2008-BUYINS.NET: NPSP, NURO, PCYC, STEN, TONE, ATNO Have Also Been Removed From Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:31032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and...

  Articles 2008-03-31

• CRZ, USS, RAK, ARQL, ETFC, NPSP Have Been Added To Naked Short List Today.

  M2 PRESSWIRE-20 March 2008-BUYINS.NET: CRZ, USS, RAK, ARQL, ETFC, NPSP Have Been Added To Naked Short List TodayC1994-2008 M2 COMMUNICATIONS LTD RDATE:20032008 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE...

  Articles 2008-03-20

• NPS Reports Successful GATTEX™ Extension Study

  Top-Line Data Confirm Pivotal Study Findings BEDMINSTER, N.J., March 17 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. today reported positive top-line results from a 28-week blinded Phase 3-extension study of GATTEXTM teduglutide for short bowel syndrome SBS patients who are dependent upon parenteral nutrition PN. The extension...

  Articles 2008-03-17

• Francois Nader

  Francois Nader has been named president and chief executive officer of NPS Pharmaceuticals Inc. Nader, who joined the company in 2006, had been executive vice president and chief operating officer...

  Articles 2008-03-17

• NPS Pharmaceuticals Reports 2007 Financial Results

  Conference call scheduled for 5:00 pm ET today BEDMINSTER, N.J., March 13 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. today reported 2007 financial results and accomplishments that reflected the implementation of a new strategy to develop the company's late-stage product candidates in specialty indications for gastrointestinal and endocrine...

  Articles 2008-03-13

• NPS Pharmaceuticals to Report 2007 Financial Results

  BEDMINSTER, N.J., March 6 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. announced today that it will report its 2007 financial results on Thursday, March 13, 2008 post-market. The announcement will be followed by a conference call and webcast at 5:00 p.m. Eastern Time. To participate in the...

  Articles 2008-03-06

• Has added NPS Pharmaceuticals Inc. to their watch list.

  M2 PRESSWIRE-3 March 2008-InvestorInstantMessaging: Has added NPS Pharmaceuticals Inc. to their watch list.C1994-2008 M2 COMMUNICATIONS LTD RDATE:03032008 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate....

  Articles 2008-03-03